Table 1.
Comparison of Clinical and Laboratory Characteristics at Baseline and the 12th Month Between Lipid-Lowering Group and Control Group
| Characteristics | Lipid-Lowering Group (n=325) | Control Group (n=216) | Baseline Comparison | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 Months | P | Baseline | 12 Months | P | P | |
| Male, n (%) | 241 (74.2) | - | - | 167 (77.3) | - | - | 0.403 |
| Age, years | 41.9±12.8 | - | - | 41.4±12.6 | - | - | 0.677 |
| Weight, kg | 72.6±12.9 | 71.6±12.5 | 0.348 | 73.7±11.5 | 73.3±11.7 | 0.733 | 0.286 |
| BMI, kg/m2 | 26.0±3.5 | 25.5±3.4 | 0.100 | 26.0±3.1 | 26.0±3.3 | 0.892 | 0.273 |
| WC, cm | 88.4±9.3 | 87.4±8.8 | 0.248 | 89.3±8.2 | 89.3±8.8 | 0.962 | 0.841 |
| SBP, mmHg | 129±16 | 129±16 | 0.995 | 128±16 | 128±15 | 0.944 | 0.583 |
| DBP, mmHg | 84±13 | 84±13 | 0.928 | 83±13 | 83±12 | 0.912 | 0.582 |
| Hypertension, n (%) | 147 (45.2) | - | - | 98 (45.4) | - | - | 0.975 |
| T2DM, n (%) | 67 (20.6) | - | - | 41 (19.0) | - | - | 0.641 |
| ALT, U/L | 80±37 | 26±15 | <0.001 | 78±34 | 74±33 | 0.145 | 0.570 |
| AST, U/L | 52±31 | 25±13 | <0.001 | 53±33 | 49±22 | 0.100 | 0.686 |
| GGT, U/L | 89±61 | 40±19 | <0.001 | 89±58 | 82±41 | 0.090 | 0.920 |
| TC, mmol/L | 6.1±1.3 | 3.6±0.7 | <0.001 | 6.0±1.0 | 5.9±1.1 | 0.611 | 0.190 |
| TG, mmol/L | 3.1±1.9 | 1.4±0.7 | <0.001 | 2.9±1.7 | 2.7±1.4 | 0.090 | 0.317 |
| HDL-c, mmol/L | 1.2±0.5 | 1.2±0.4 | 0.453 | 1.2±0.4 | 1.2±0.4 | 0.827 | 0.307 |
| LDL-c, mmol/L | 4.0±0.9 | 2.5±0.8 | <0.001 | 3.9±0.8 | 3.8±0.7 | 0.175 | 0.656 |
| ApoA-1, g/L | 1.4±0.5 | 1.4±0.3 | 0.995 | 1.3±0.3 | 1.4±0.3 | 0.250 | 0.521 |
| ApoB, g/L | 1.1±0.3 | 1.0±0.3 | 0.001 | 1.1±0.2 | 1.0±0.2 | 0.097 | 0.112 |
| ApoE, mg/L | 57±28 | 47±25 | <0.001 | 54±22 | 57±40 | 0.451 | 0.276 |
| Lp-A, mg/L | 204±192 | 202±209 | 0.884 | 193±179 | 199±190 | 0.840 | 0.631 |
| UA, μmol/l | 416±104 | 393±103 | 0.015 | 415±106 | 407±116 | 0.700 | 0.966 |
| FFA, mmol/L | 572±220 | 418±118 | <0.001 | 543±177 | 509±162 | 0.264 | 0.353 |
| FBG, mmol/L | 5.6±1.2 | 5.4±1.0 | 0.006 | 5.5±1.3 | 5.3±1.2 | 0.213 | 0.453 |
| FINS, μU/mL | 12.1±9.6 | 11.3±8.6 | 0.328 | 11.5±6.0 | 11.5±7.9 | 0.956 | 0.552 |
| HOMA-IR | 3.1±3.2 | 3.0±2.8 | 0.655 | 2.8±1.7 | 2.8±1.9 | 0.813 | 0.336 |
| HbA1c, % | 6.1±1.1 | 5.9±1.1 | 0.735 | 6.1±1.2 | 5.8±1.1 | 0.219 | 0.981 |
| FIB-4 index | 1.27±0.95 | 1.23±0.80 | 0.756 | 1.25±0.77 | 1.19±0.67 | 0.643 | 0.904 |
| NFS | −1.36±1.62 | −1.70±2.03 | 0.366 | −1.48±1.82 | −2.12±2.35 | 0.325 | 0.728 |
| LSM, kPa | 6.5±2.4 | 6.4±2.3 | 0.700 | 6.1±1.6 | 6.6±2.0 | 0.239 | 0.277 |
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, type 2 diabetes; ALT, alanine aminotransferease; AST, aspartate aminotransferase; GGT, gamma glutamyltranspeptidase; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ApoE, apolipoprotein E; LP-A, lipoprotein-A; UA, uric acid; FFA, free fatty acid; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, glycated hemoglobin; FIB-4, Fibrosis-4; NFS, NAFLD fibrosis score; LSM, liver stiffness measurement.